Serum Soluble HLA-E in Melanoma: A New Potential Immune-Related Marker in Cancer
Author Information
Author(s): Allard Mathilde, Oger Romain, Vignard Virginie, Percier Jean-Michel, Fregni Giulia, Périer Aurélie, Caignard Anne, Charreau Béatrice, Bernardeau Karine, Khammari Amir, Dréno Brigitte, Gervois Nadine
Primary Institution: UMR INSERM, U892, Nantes, France
Hypothesis
Can soluble HLA-E levels serve as a tumor-associated marker in melanoma patients?
Conclusion
Serum levels of soluble HLA-E are significantly increased in melanoma patients compared to healthy individuals, suggesting its potential as a clinical marker.
Supporting Evidence
- Serum sHLA-E levels were significantly elevated in melanoma patients compared to healthy donors.
- 68 out of 127 melanoma patients had detectable sHLA-E, compared to 30 out of 94 healthy donors.
- Stage III melanoma patients exhibited significantly higher sHLA-E levels compared to healthy donors.
Takeaway
This study found that a substance called soluble HLA-E is much higher in people with melanoma than in healthy people, which might help doctors understand and treat cancer better.
Methodology
A specific ELISA was developed to quantify soluble HLA-E levels in serum samples from melanoma patients and healthy donors.
Limitations
The study did not find significant associations between serum sHLA-E levels and melanoma stage, which may be due to unequal distribution of patients across subgroups.
Participant Demographics
127 melanoma patients and 94 healthy donors, with no significant differences in sHLA-E levels based on age and gender.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website